Anna CzÅ‚onkowska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3332316/publications.pdf

Version: 2024-02-01

312	17,706	25034 57	17592 121
papers	citations	h-index	g-index

325	325	325	19892
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antiplatelet drugs and liver fibrosis. Platelets, 2022, 33, 219-228.	2.3	11
2	Wilsonâ€™s disease- management and long term outcomes. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 56-57, 101768.	2.4	7
3	Liver transplantation as a treatment for Wilsonâ€™s disease with neurological presentation: a systematic literature review. Acta Neurologica Belgica, 2022, 122, 505-518.	1.1	8
4	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Movement Disorders, 2022, 37, 1074-1079.	3.9	16
5	Brain magnetic resonance imaging and severity of neurological disease in Wilsonâ€™s disease â€" the neuroradiological correlations. Neurological Sciences, 2022, 43, 4405-4412.	1.9	11
6	Sleep disturbances in newly diagnosed treatment-naÃ¯ve patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2022, 122, 745-751.	1.1	3
7	Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke. International Journal of Molecular Sciences, 2022, 23, 4530.	4.1	8
8	Liver injury in Wilson's disease: An immunohistochemical study. Advances in Medical Sciences, 2022, 67, 203-207.	2.1	0
9	The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis. Molecular Neurobiology, 2022, 59, 4651-4668.	4.0	3
10	Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review. Molecular Neurobiology, 2021, 58, 1664-1682.	4.0	30
11	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. Heart, 2021, 107, 282-289.	2.9	25
12	The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Molecular Neurobiology, 2021, 58, 329-347.	4.0	78
13	Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology, 2021, 96, e2824-e2838.	1.1	95
14	Clinical significance of self-descriptive apathy assessment in patients with neurological form of Wilsonâ€™s disease. Neurological Sciences, 2021, , 1.	1.9	3
15	Designing Clinical Trials in Wilsonâ€™s Disease. Hepatology, 2021, 74, 3460-3471.	7.3	12
16	Clinical and laboratory parameters by age for patients diagnosed with multiple sclerosis between 2000 and 2015. Neurologia I Neurochirurgia Polska, 2021, 55, 387-393.	1.2	1
17	Diagnosis of Wilson Disease and Its Phenotypes by Using Artificial Intelligence. Biomolecules, 2021, 11, 1243.	4.0	6
18	Wilsonâ€™s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1053-1061.	1.9	44

#	Article	IF	Citations
19	Evaluation of liver fibrosis in patients with Wilsonâ€™s disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 535-540.	1.6	14
20	Autonomic nervous system dysfunction in Wilson's disease â€“ A systematic literature review. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102890.	2.8	2
21	D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilsonâ€™s Disease. Neurologia I Neurochirurgia Polska, 2021, 55, 595-597.	1.2	7
22	Blink reflex in newly diagnosed and treated patients with Wilsonâ€™s disease. Journal of Neural Transmission, 2021, 128, 1873-1880.	2.8	1
23	Perspectives of Wilsonâ€™s disease treatment. Pharmacotherapy in Psychiatry and Neurology, 2021, 37, .	0.1	0
24	Gastropathy in patients with Wilson disease. Scandinavian Journal of Gastroenterology, 2020, 55, 14-17.	1.5	7
25	Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Movement Disorders, 2020, 35, 994-1001.	3.9	43
26	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 2386-2394.	2.0	18
27	Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. Neurological Sciences, 2020, 41, 2605-2612.	1.9	3
28	mtDNA depletionâ€like syndrome in Wilson disease. Liver International, 2020, 40, 2776-2787.	3.9	7
29	Cerebrovascular reactivity and disease activity in relapsing-remitting multiple sclerosis. Advances in Clinical and Experimental Medicine, 2020, 29, 183-188.	1.4	9
30	Fluoxetine for stroke recovery improvement â€“ the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia I Neurochirurgia Polska, 2020, 54, 544-551.	1.2	4
31	Transcranial sonography changes in patients with Wilsonâ€™s Disease during de-coppering therapy. Neurologia I Neurochirurgia Polska, 2020, 54, 185-192.	1.2	0
32	Prediction of Recovery and Outcome Using Motor Evoked Potentials and Brain Derived Neurotrophic Factor in Subacute Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105202.	1.6	6
33	Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence. Orphanet Journal of Rare Diseases, 2019, 14, 167.	2.7	8
34	Treatment of Wilsonâ€™s disease â€“ an update. Expert Opinion on Orphan Drugs, 2019, 7, 287-294.	0.8	2
35	Neurologic impairment in Wilson disease. Annals of Translational Medicine, 2019, 7, S64-S64.	1.7	58
36	Neurological Wilson Disease. , 2019, , 145-157.		1

#	Article	IF	Citations
37	Brain volume is related to neurological impairment and to copper overload in Wilsonâ€™s disease. Neurological Sciences, 2019, 40, 2089-2095.	1.9	27
38	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2273-2279.	1.6	27
39	Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature. Metabolomics, 2019, 15, 43.	3.0	26
40	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics and Chromatin, 2019, 12, 10.	3.9	32
41	Persistence with treatment for Wilson disease: a retrospective study. BMC Neurology, 2019, 19, 278.	1.8	30
42	Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes. International Journal of Molecular Sciences, 2019, 20, 5937.	4.1	22
43	Wholeâ€exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype. Liver International, 2019, 39, 177-186.	3.9	38
44	Cardiac assessment in Wilsonâ€™s disease patients based on electrocardiography and echocardiography examination. Archives of Medical Science, 2019, 15, 857-864.	0.9	17
45	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology, 2019, 69, 1464-1476.	7.3	110
46	Oral Chelator Treatment of Wilson Disease. , 2019, , 357-364.		4
47	Wilson diseaseâ€”treatment perspectives. Annals of Translational Medicine, 2019, 7, S68-S68.	1.7	34
48	Difficulties in diagnosis and treatment of Wilson diseaseâ€”a case series of five patients. Annals of Translational Medicine, 2019, 7, S73-S73.	1.7	8
49	Clinical manifestations of Wilson disease in organs other than the liver and brain. Annals of Translational Medicine, 2019, 7, S62-S62.	1.7	38
50	Increased burden of rare deleterious variants of the KCNQ1 gene in patients with largeâ€‘vessel ischemic stroke. Molecular Medicine Reports, 2019, 19, 3263-3272.	2.4	3
51	Embolic strokes of undetermined source in a cohort of Polish stroke patients. Neurological Sciences, 2018, 39, 1041-1047.	1.9	13
52	Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilsonâ€™s Disease Rating Scale. BMC Neurology, 2018, 18, 34.	1.8	43
53	Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver International, 2018, 38, 1860-1866.	3.9	26
54	Psychiatric manifestations in Wilsonâ€™s disease: possibilities and difficulties for treatment. Therapeutic Advances in Psychopharmacology, 2018, 8, 199-211.	2.7	68

#	Article	IF	Citations
55	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
56	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1673-1682.	1.6	46
57	Transcranial Sonography in Mitochondrial Membrane Protein-Associated Neurodegeneration. Clinical Neuroradiology, 2018, 28, 385-392.	1.9	5
58	Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurologia I Neurochirurgia Polska, 2018, 52, 98-101.	1.2	8
59	Differences in carotid artery atherosclerosis between men and women in the early phase after ischemic event. Neurologia I Neurochirurgia Polska, 2018, 52, 162-167.	1.2	6
60	Noninfectious complications of acute stroke and their impact on hospital mortality in patients admitted to a stroke unit in Warsaw from 1995 to 2015. Neurologia I Neurochirurgia Polska, 2018, 52, 168-173.	1.2	4
61	Measurement of Nutritional Status Using Body Mass Index, Waist-to-Hip Ratio, and Waist Circumference to Predict Treatment Outcome in Females and Males with Acute First-Ever Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 132-139.	1.6	16
62	Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial. Translational Stroke Research, 2018, 9, 120-129.	4.2	8
63	MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Strokeâ€”A Comprehensive Review and Bioinformatic Analysis. Cells, 2018, 7, 249.	4.1	131
64	Neuropsychiatric presentation of Wilsonâ€™s disease â€“ a case report. Neuropsychiatria I Neuropsychologia, 2018, 13, 31-42.	0.4	1
65	Wilson disease. Nature Reviews Disease Primers, 2018, 4, 21.	30.5	466
66	WTX101 â€“ an investigational drug for the treatment of Wilson disease. Expert Opinion on Investigational Drugs, 2018, 27, 561-567.	4.1	21
67	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	13.7	96
68	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet, The, 2018, 391, 2107-2115.	13.7	309
69	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine, 2018, 378, 2191-2201.	27.0	730
70	Acute Ischemic Stroke Hospital Admissions, Treatment, and Outcomes in Poland in 2009â€“2013. Frontiers in Neurology, 2018, 9, 134.	2.4	8
71	Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease. Human Molecular Genetics, 2018, 27, 3854-3869.	2.9	18
72	Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. Lancet Neurology, The, 2018, 17, 587-596.	10.2	114

#	Article	IF	Citations
73	Infections Diagnosed after Admission to a Stroke Unit and Their Impact on Hospital Mortality in Poland from 1995 to 2015. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1775-1782.	1.6	2
74	Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod. Neurologia I Neurochirurgia Polska, 2017, 51, 156-162.	1.2	24
75	Effect of medical complications on the after-stroke rehabilitation outcome. NeuroRehabilitation, 2017, 40, 223-232.	1.3	36
76	Wilson disease â€“ currently used anticopper therapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 181-191.	1.8	47
77	Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry. Journal of Neurology, 2017, 264, 912-920.	3.6	27
78	Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12. Parkinsonism and Related Disorders, 2017, 39, 71-76.	2.2	22
79	Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. The Lancet Gastroenterology and Hepatology, 2017, 2, 869-876.	8.1	110
80	A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase. Journal of Hepatology, 2017, 67, 1026-1030.	3.7	18
81	Infections Up to 76ÂDays After Stroke Increase Disability and Death. Translational Stroke Research, 2017, 8, 541-548.	4.2	25
82	Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases. Stroke, 2017, 48, 2263-2265.	2.0	12
83	Mechanical thrombectomy in acute stroke â€“ Five years of experience in Poland. Neurologia I Neurochirurgia Polska, 2017, 51, 339-346.	1.2	11
84	Optical coherence tomography as a marker of neurodegeneration in patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2017, 117, 867-871.	1.1	22
85	Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI â€“ histopathological study. Neuropathology and Applied Neurobiology, 2017, 43, 514-532.	3.2	60
86	Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA. Journal of Thrombosis and Thrombolysis, 2017, 44, 362-370.	2.1	12
87	Population-Specific Associations of Deleterious Rare Variants in Coding Region of P2RY1â€“P2RY12 Purinergic Receptor Genes in Large-Vessel Ischemic Stroke Patients. International Journal of Molecular Sciences, 2017, 18, 2678.	4.1	10
88	Other organ involvement and clinical aspects of Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 157-169.	1.8	28
89	Symptomatic treatment of neurologic symptoms in Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 211-223.	1.8	39
90	Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome. Thrombosis and Haemostasis, 2017, 117, 1440-1447.	3.4	27

#	Article	IF	Citations
91	Assessment of brain cortical atrophy in neurodegenerative as well as selected neurological disorders â€“ assessment methods and significance in diagnosis. Neuropsychiatria I Neuropsychologia, 2017, 1, 20-29.	0.4	1
92	Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 101-119.	1.8	52
93	Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016. Kardiologia Polska, 2017, 75, 187-190.	0.6	2
94	Polish Forum for Prevention Guidelines on Hypertension: update 2017. Kardiologia Polska, 2017, 75, 282-285.	0.6	9
95	Polish Forum for Prevention Guidelines on Smoking: update 2017. Kardiologia Polska, 2017, 75, 409-411.	0.6	7
96	Polish Forum for Prevention Guidelines on Prophylactic Pharmacotherapy: update 2017. Kardiologia Polska, 2017, 75, 508-511.	0.6	1
97	Polish Forum for Prevention Guidelines on Diabetes: update 2017. Kardiologia Polska, 2017, 75, 628-631.	0.6	1
98	Polish Forum for Prevention Guidelines on Cardiovascular Risk Assessment: update 2016. Kardiologia Polska, 2017, 75, 84-86.	0.6	2
99	Disorders resulting from transporter defects. , 2016, , 687-693.		0
100	Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013. Archives of Medical Science, 2016, 4, 754-759.	0.9	5
101	Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction. Croatian Medical Journal, 2016, 57, 548-557.	0.7	16
102	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal, 2016, 1, 146-154.	5.5	83
103	Novel mutation of the NOTCH3 gene in a Polish family with CADASIL. Neurologia I Neurochirurgia Polska, 2016, 50, 262-264.	1.2	7
104	Small intracerebral hemorrhages have a low spot sign prevalence and are less likely to expand. International Journal of Stroke, 2016, 11, 191-197.	5.9	18
105	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. International Journal of Stroke, 2016, 11, 683-694.	5.9	50
106	Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN). Journal of the Neurological Sciences, 2016, 370, 237-240.	0.6	11
107	Cerebral vasomotor reactivity in neurodegenerative diseases. Neurologia I Neurochirurgia Polska, 2016, 50, 455-462.	1.2	29
108	Ultraearly hematoma growth in active intracerebral hemorrhage. Neurology, 2016, 87, 357-364.	1.1	50

#	Article	IF	Citations
109	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, The, 2016, 388, 761-775.	13.7	1,414
110	The sunflower cataract in Wilsonâ€™s disease: pathognomonic sign or rare finding?. Acta Neurologica Belgica, 2016, 116, 325-328.	1.1	31
111	Neurological manifestations in Wilsonâ€™s disease â€“possible treatment options for symptoms. Expert Opinion on Orphan Drugs, 2016, 4, 719-728.	0.8	14
112	Optical coherence tomography and electrophysiology of retinal and visual pathways in Wilsonâ€™s disease. Metabolic Brain Disease, 2016, 31, 405-415.	2.9	26
113	Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome. International Journal of Clinical Practice, 2016, 70, 477-481.	1.7	5
114	Glyceryl Trinitrate for Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 44-52.	2.0	32
115	Adding transcutaneous electrical nerve stimulation to visual scanning training does not enhance treatment effect on hemispatial neglect: a randomized, controlled, double-blind study. Topics in Stroke Rehabilitation, 2016, 23, 377-383.	1.9	5
116	Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis. Stroke, 2016, 47, 652-658.	2.0	48
117	Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1017-1026.	1.6	8
118	Perihematomal Edema Is Greater in the Presence of a Spot Sign but Does Not Predict Intracerebral Hematoma Expansion. Stroke, 2016, 47, 350-355.	2.0	16
119	Psychiatric disturbances as a first clinical symptom of Wilsonâ€™s disease â€“ case report.. Psychiatria Polska, 2016, 50, 337-344.	0.5	12
120	Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilsonâ€™s disease.. Neuropsychology, 2015, 29, 25-30.	1.3	34
121	Management of ischemic stroke in Central and Eastern Europe. International Journal of Stroke, 2015, 10, 125-127.	5.9	19
122	The accuracy of prehospital diagnosis of acute cerebrovascular accidents: an observational study. Archives of Medical Science, 2015, 3, 530-535.	0.9	19
123	Gene variants encoding proteins involved in antioxidant defense system and the clinical expression of Wilson disease. Liver International, 2015, 35, 215-222.	3.9	17
124	Treatment of Wilsonâ€™s disease â€“ another point of view. Expert Opinion on Orphan Drugs, 2015, 3, 239-243.	0.8	5
125	Safety of Statin Pretreatment in Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke, 2015, 46, 2681-2684.	2.0	27
126	Early neurological worsening in patients with Wilson's disease. Journal of the Neurological Sciences, 2015, 355, 162-167.	0.6	116

#	Article	IF	Citations
127	Eye of the tiger sign in a 23year patient with mitochondrial membrane protein associated neurodegeneration. Journal of the Neurological Sciences, 2015, 352, 110-111.	0.6	13
128	Sunflower cataract: do not forget Wilson's disease. Practical Neurology, 2015, 15, 385-386.	1.1	10
129	Alteplase for Acute Ischemic Stroke. Stroke, 2015, 46, 746-756.	2.0	74
130	TMSâ€induced motor evoked potentials in Wilson's disease: A systematic literature review. Bioelectromagnetics, 2015, 36, 255-266.	1.6	4
131	The Activity of Malignancy May Determine Stroke Pattern in Cancer Patients. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 778-783.	1.6	30
132	Frequencies of initial gait disturbances and falls in 100 Wilson's disease patients. Gait and Posture, 2015, 42, 601-603.	1.4	13
133	Hepatobiliary malignancies in Wilson disease. Liver International, 2015, 35, 1615-1622.	3.9	78
134	Intracerebral Hematoma Morphologic Appearance on Noncontrast Computed Tomography Predicts Significant Hematoma Expansion. Stroke, 2015, 46, 3111-3116.	2.0	103
135	Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event. Stroke, 2015, 46, 3184-3189.	2.0	19
136	Evolution of diagnostic criteria for multiple sclerosis. Neurologia I Neurochirurgia Polska, 2015, 49, 313-321.	1.2	17
137	Temporal trends in vascular risk factors and etiology of urban Polish stroke patients from 1995 to 2013. Journal of the Neurological Sciences, 2015, 357, 126-130.	0.6	12
138	Wilson Disease and Other Neurodegenerations with Metal Accumulations. Neurologic Clinics, 2015, 33, 175-204.	1.8	76
139	The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15Âyears. International Journal of Clinical Practice, 2015, 69, 180-185.	1.7	6
140	Encephalopathy in Wilson Disease: Copper Toxicity or Liver Failure?. Journal of Clinical and Experimental Hepatology, 2015, 5, S88-S95.	0.9	31
141	Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilsonï¿½s disease. Functional Neurology, 2015, 30, 264-8.	1.3	14
142	A survey to establish current methods of venous thromboembolism prophylaxis in stroke patients practiced by Polish neurologists. Archives of Medical Science, 2014, 3, 470-476.	0.9	0
143	APOEÏµ2 allele is an independent risk factor for vulnerable carotid plaque in ischemic stroke patients. Neurological Research, 2014, 36, 950-954.	1.3	8
144	Compliant treatment with antiâ€copper agents prevents clinically overt <scp>W</scp>ilson's disease in preâ€symptomatic patients. European Journal of Neurology, 2014, 21, 332-337.	3.3	70

#	Article	IF	Citations
145	Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurologica Scandinavica, 2014, 130, 305-311.	2.1	27
146	Effects of Repeated Anodal tDCS Coupled With Cognitive Training for Patients With Severe Traumatic Brain Injury. Journal of Head Trauma Rehabilitation, 2014, 29, E20-E29.	1.7	65
147	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2014, 20, 705-716.	3.0	295
148	Venous Phase of Computed Tomography Angiography Increases Spot Sign Detection, but Intracerebral Hemorrhage Expansion Is Greater in Spot Signs Detected in Arterial Phase. Stroke, 2014, 45, 734-739.	2.0	51
149	Concordance rates of Wilson's disease phenotype among siblings. Journal of Inherited Metabolic Disease, 2014, 37, 131-135.	3.6	22
150	Multiple sclerosis in two patients with coexisting Wilson's disease. Multiple Sclerosis and Related Disorders, 2014, 3, 387-390.	2.0	4
151	Dâ€penicillamine versus zinc sulfate as firstâ€line therapy for Wilson's disease. European Journal of Neurology, 2014, 21, 599-606.	3.3	113
152	Hyperdense Cerebral Artery Computed Tomography Sign Is Associated with Stroke Severity Rather than Stroke Subtype. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2533-2539.	1.6	15
153	Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke. Stroke, 2014, 45, 770-775.	2.0	60
154	MR image mimicking the â€œeye of the tigerâ€•sign in Wilsonâ€™s disease. Journal of Neurology, 2014, 261, 1025-1027.	3.6	15
155	Lenticular nucleus hyperechogenicity in Wilsonâ€™s disease reflects local copper, but not iron accumulation. Journal of Neural Transmission, 2014, 121, 1273-1279.	2.8	24
156	The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease. Pharmacological Reports, 2014, 66, 660-669.	3.3	35
157	Is there a bad time for intravenous thrombolysis? The experience of Polish stroke centers. Neurologia I Neurochirurgia Polska, 2014, 48, 45-51.	1.2	3
158	Polymorphisms of metal transporter genes DMT1 and ATP7A in Wilson's disease. Journal of Trace Elements in Medicine and Biology, 2014, 28, 8-12.	3.0	22
159	Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate. Neurologia I Neurochirurgia Polska, 2014, 48, 214-218.	1.2	32
160	Families with Wilson's disease in subsequent generations: Clinical and genetic analysis. Movement Disorders, 2014, 29, 1828-1832.	3.9	18
161	Jak postÄ™powaÄ‡ w zwÄ™Å¼eniu tÄ™tnic szyjnych u kobiet? KrÃ³tki przeglÄ…d wybranych badaÅ„ i wytycznych. Postepy Psychiatrii I Neurologii, 2014, 23, 156-161.	0.2	0
162	Impact ofBDNF-196 G>A andBDNF-270 C>T Polymorphisms on Stroke Rehabilitation Outcome: Sex and Age Differences. Topics in Stroke Rehabilitation, 2014, 21, S33-S41.	1.9	22

#	Article	IF	Citations
163	Prevention of ischemic stroke in clinical practice: a role of internists and general practitioners. Polish Archives of Internal Medicine, 2014, 124, 540-548.	0.4	10
164	Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. Functional Neurology, 2014, 29, 23-9.	1.3	15
165	Do silent infarcts modify the effect of thrombolysis for stroke?. Acta Neurologica Scandinavica, 2013, 127, 227-232.	2.1	3
166	Influence of BDNF polymorphisms on Wilsonâ€™s disease susceptibility and clinical course. Metabolic Brain Disease, 2013, 28, 447-453.	2.9	8
167	The effect of gender on brain MRI pathology in Wilsonâ€™s disease. Metabolic Brain Disease, 2013, 28, 69-75.	2.9	42
168	Prestroke Antihypertensive Therapy: Effect on the Outcome. Clinical and Experimental Hypertension, 2013, 35, 141-147.	1.3	7
169	Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs-associated outcomes in real-world practice â€“ findings from the Polish Hospital Stroke Registry. Neurologia I Neurochirurgia Polska, 2013, 47, 517-524.	1.2	4
170	Does brain degeneration in Wilson disease involve not only copper but also iron accumulation?. Neurologia I Neurochirurgia Polska, 2013, 47, 542-546.	1.2	27
171	Positivity of serum â€œclassicalâ€•onconeural antibodies in a series of 2063 consecutive patients with suspicion of paraneoplastic neurological syndrome. Journal of Neuroimmunology, 2013, 259, 75-80.	2.3	8
172	Intestinal expression of metal transporters in Wilsonâ€™s disease. BioMetals, 2013, 26, 925-934.	4.1	14
173	Stroke Care in Central Eastern Europe: Current Problems and Call for Action. International Journal of Stroke, 2013, 8, 365-371.	5.9	12
174	Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 393-397.	1.2	12
175	No effects of anodal transcranial direct stimulation on language abilities in early rehabilitation of post-stroke aphasic patients. Neurologia I Neurochirurgia Polska, 2013, 47, 414-422.	1.2	32
176	Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 502-506.	1.2	17
177	Pharmacotherapy prior to and in acute ischaemic stroke. The use of pharmacotherapy and drugs-associated outcomes in real-world practice â€“ findings from the Polish Hospital Stroke Registry. Neurologia I Neurochirurgia Polska, 2013, 47, 509-516.	1.2	4
178	Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease. Pharmacological Reports, 2013, 65, 44-49.	3.3	28
179	Venous thromboembolism prophylactic methods in acute stroke patients â€“ current state of knowledge. Neurologia I Neurochirurgia Polska, 2013, 47, 564-571.	1.2	3
180	Brain metal accumulation in Wilson's disease. Journal of the Neurological Sciences, 2013, 329, 55-58.	0.6	77

#	Article	IF	Citations
181	Transcranial sonography in mitochondrial membrane protein-associated neurodegeneration. Parkinsonism and Related Disorders, 2013, 19, 1061-1063.	2.2	7
182	Organization of acute stroke services in Poland â€“ Polish Stroke Unit Network development. Neurologia I Neurochirurgia Polska, 2013, 47, 3-7.	1.2	11
183	Spot Sign Number Is the Most Important Spot Sign Characteristic for Predicting Hematoma Expansion Using First-Pass Computed Tomography Angiography. Stroke, 2013, 44, 972-977.	2.0	61
184	Anodal transcranial direct current stimulation in early rehabilitation of patients with post-stroke non-fluent aphasia: A randomized, double-blind, sham-controlled pilot study. Restorative Neurology and Neuroscience, 2013, 31, 761-771.	0.7	42
185	Association between BDNF-196 G>A and BDNF-270 C>T polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation outcome after ischemic stroke. NeuroRehabilitation, 2013, 32, 573-582.	1.3	27
186	Lithium Treatment of a Bipolar Patient with Wilson's Disease: A Case Report. Pharmacopsychiatry, 2013, 46, 120-121.	3.3	14
187	Hyperperfusion Syndrome after Carotid Endarterectomy and Carotid Stenting. Cerebrovascular Diseases, 2013, 35, 531-537.	1.7	36
188	Transcranial Magnetic Stimulation Combined with Speech and Language Training in Early Aphasia Rehabilitation: A Randomized Double-Blind Controlled Pilot Study. Topics in Stroke Rehabilitation, 2013, 20, 250-261.	1.9	81
189	Knowledge of Risk Factors and Stroke Symptoms among Nonstroke Patients. European Neurology, 2012, 67, 220-225.	1.4	18
190	Effects of sling and voluntary constraint during constraint-induced movement therapy for the arm after stroke: a randomized, prospective, single-centre, blinded observer rated study. Clinical Rehabilitation, 2012, 26, 990-998.	2.2	9
191	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, The, 2012, 379, 2352-2363.	13.7	1,018
192	Transcranial Magnetic Stimulation Combined With Physiotherapy in Rehabilitation of Poststroke Hemiparesis. Neurorehabilitation and Neural Repair, 2012, 26, 1072-1079.	2.9	94
193	Weekend versus weekday admissions in Polish stroke centres â€“ could admission day affect prognosis in Polish ischaemic stroke patients?. Neurologia I Neurochirurgia Polska, 2012, 46, 15-21.	1.2	14
194	Apolipoprotein E gene (APOE) genotype in Wilsonâ€™s disease: Impact on clinical presentation. Parkinsonism and Related Disorders, 2012, 18, 367-369.	2.2	42
195	Wilson's disease: does iron metabolism impact phenotypic presentation?. Liver International, 2012, 32, 869-870.	3.9	5
196	Factors Influencing In-Hospital Delay in Treatment With Intravenous Thrombolysis. Stroke, 2012, 43, 1578-1583.	2.0	104
197	BDNF â^'270 C>T polymorphisms might be associated with stroke type and BDNF â^'196 G>A corresponds to early neurological deficit in hemorrhagic stroke. Journal of Neuroimmunology, 2012, 249, 71-75.	2.3	31
198	Gender differences in Wilson's disease. Journal of the Neurological Sciences, 2012, 312, 31-35.	0.6	119

#	Article	IF	Citations
199	Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland. Neurologia I Neurochirurgia Polska, 2012, 46, 3-14.	1.2	16
200	Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Naming Abilities in Early-Stroke Aphasic Patients: A Prospective, Randomized, Double-Blind Sham-Controlled Study. Scientific World Journal, The, 2012, 2012, 1-8.	2.1	66
201	Deep Venous Thrombosis in Acute Stroke Patients. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 258-264.	1.7	20
202	Intravenous Alteplase in Ischemic Stroke Patients not Fully Adhering to the Current Drug License in Central and Eastern Europe. International Journal of Stroke, 2012, 7, 615-622.	5.9	44
203	Development of early comprehensive stroke inpatient rehabilitation in Poland â€“ current status and future requirements. Neurologia I Neurochirurgia Polska, 2011, 45, 245-251.	1.2	2
204	Incidence and case fatality rates of first-ever stroke â€“ comparison of data from two prospective population-based studies conducted in Warsaw. Neurologia I Neurochirurgia Polska, 2011, 45, 207-212.	1.2	22
205	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials, 2011, 12, 252.	1.6	38
206	Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilsonâ€™s disease. Journal of Hepatology, 2011, 55, 913-919.	3.7	47
207	Early stroke-related DVT is more than just DVT diagnosed early after stroke onset. Thrombosis Research, 2011, 128, 587-589.	1.7	3
208	Infections and Ischemic Stroke Outcome. Neurology Research International, 2011, 2011, 1-8.	1.3	22
209	Inflammation and gliosis in neurological diseases â€“ clinical implications. Journal of Neuroimmunology, 2011, 231, 78-85.	2.3	78
210	Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-Î± polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2011, 236, 87-92.	2.3	51
211	The International Stroke Trial database. Trials, 2011, 12, 101.	1.6	59
212	Early stroke-related deep venous thrombosis: risk factors and influence on outcome. Journal of Thrombosis and Thrombolysis, 2011, 32, 96-102.	2.1	54
213	Planning trials in older patients with stroke: data from the International Stroke Trial. Age and Ageing, 2011, 40, 395-398.	1.6	3
214	Influence ofIL-1RNIntron 2 Variable Number of Tandem Repeats (VNTR) Polymorphism on the Age at Onset of Neuropsychiatric Symptoms in Wilson's Disease. International Journal of Neuroscience, 2011, 121, 8-15.	1.6	22
215	Polymorphisms in the factor VII gene and ischemic stroke in young adults. Blood Coagulation and Fibrinolysis, 2010, 21, 442-447.	1.0	21
216	Clinical features of hemolysis, elevated liver enzymes, and low platelet count syndrome in undiagnosed Wilson disease: report of two cases. Archives of Gynecology and Obstetrics, 2010, 281, 129-134.	1.7	28

#	Article	IF	Citations
217	Middle-aged heterozygous carriers of Wilsonâ€™s disease do not present with significant phenotypic deviations related to copper metabolism. Journal of Genetics, 2010, 89, 463-467.	0.7	35
218	Brain proton magnetic spectroscopy in long-term treatment of Wilsonâ€™s disease patients. Metabolic Brain Disease, 2010, 25, 325-329.	2.9	8
219	Brain proton magnetic spectroscopy in long-term treatment of Wilsonâ€™s disease patients. Metabolic Brain Disease, 2010, 25, 375-379.	2.9	0
220	Downâ€regulation of microglia and NG2â€positive cells reaction in trimethyltinâ€injured hippocampus of rats treated with myelin basic proteinâ€reactive T cells: Possible contribution to the neuroprotective effect of T cells. Journal of Neuroscience Research, 2010, 88, 24-32.	2.9	5
221	Ten Years of Stroke Programmes in Poland: Where Did we Start? Where Did we Get To?. International Journal of Stroke, 2010, 5, 414-416.	5.9	13
222	How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data?. International Journal of Stroke, 2010, 5, 430-431.	5.9	8
223	Care for patients after stroke. Results of a two-year prospective observational study from Mazowieckie province in Poland. Neurologia I Neurochirurgia Polska, 2010, 44, 231-237.	1.2	9
224	Persistence with treatment in patients with Wilson disease. Neurologia I Neurochirurgia Polska, 2010, 44, 260-263.	1.2	54
225	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE) Tj ETQq1 1 0.784314 rgBT /Overlo	13.7	2,565
226	Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients. Immunopharmacology and Immunotoxicology, 2010, 32, 416-421.	2.4	5
227	Are cognitive and behavioural deficits a part of the clinical picture in Kennedy's disease? A case study. Neurocase, 2009, 15, 332-337.	0.6	10
228	Pharmacotherapy in stroke rehabilitation. Expert Opinion on Pharmacotherapy, 2009, 10, 1249-1259.	1.8	15
229	Pulse Pressure â€“ Independent Predictor of Poor Early Outcome and Mortality following Ischemic Stroke. Cerebrovascular Diseases, 2009, 27, 187-192.	1.7	23
230	Risk factors for falls in stroke patients during inpatient rehabilitation. Clinical Rehabilitation, 2009, 23, 176-188.	2.2	107
231	Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2009, 214, 113-117.	2.3	26
232	Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 2009, 1261, 7-19.	2.2	38
233	Monozygotic female twins discordant for phenotype of Wilson's disease. Movement Disorders, 2009, 24, 1066-1069.	3.9	72
234	Heterozygous carriers for Wilsonâ€™s diseaseâ€”magnetic spectroscopy changes in the brain. Metabolic Brain Disease, 2009, 24, 463-468.	2.9	17

#	Article	IF	Citations
235	New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. Journal of the Neurological Sciences, 2009, 283, 214-218.	0.6	61
236	Oxfordshire Community Stroke Project Clinical Stroke Syndrome and Appearances of Tissue and Vascular Lesions on Pretreatment CT in Hyperacute Ischemic Stroke Among the First 510 Patients in the Third International Stroke Trial (IST-3). Stroke, 2009, 40, 743-748.	2.0	31
237	The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials, 2008, 9, 37.	1.6	86
238	Informed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudes. Trials, 2008, 9, 45.	1.6	17
239	Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Movement Disorders, 2008, 23, 54-62.	3.9	94
240	Neurological presentation of Wilson's disease in a patient after liver transplantation. Movement Disorders, 2008, 23, 743-746.	3.9	29
241	Late onset Wilson's disease: Therapeutic implications. Movement Disorders, 2008, 23, 896-898.	3.9	67
242	MR spectroscopy in monitoring the treatment of Wilson's disease patients. Movement Disorders, 2008, 23, 1560-1566.	3.9	33
243	Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson's disease. Movement Disorders, 2008, 23, 2067-2073.	3.9	22
244	EPITHETâ€"where next?. Lancet Neurology, The, 2008, 7, 570-571.	10.2	6
245	BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the polish population. Gender differences. Journal of Neuroimmunology, 2008, 193, 170-172.	2.3	36
246	Frequency and Prognostic Value of Cognitive Disorders in Stroke Patients. Dementia and Geriatric Cognitive Disorders, 2008, 26, 356-363.	1.5	255
247	Efficacy and Safety of Botulinum Type A Toxin in Adductor Spasticity Due to Multiple Sclerosis. Journal of Musculoskeletal Pain, 2008, 16, 175-188.	0.3	15
248	APOE does not predict poor outcome 1 year after ischemic stroke. Neurological Research, 2007, 29, 64-69.	1.3	11
249	Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated. Emergency Medicine Journal, 2007, 24, 96-99.	1.0	19
250	Anti-myelin basic protein T cells protect hippocampal neurons against trimethyltin-induced damage. NeuroReport, 2007, 18, 425-429.	1.2	9
251	Late-Onset Wilsonâ€™s Disease. Gastroenterology, 2007, 132, 1294-1298.	1.3	227
252	Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinsonâ€™s Disease. NeuroImmunoModulation, 2007, 14, 255-265.	1.8	26

#	Article	IF	Citations
253	Stroke Service in Central and Eastern Europe. International Journal of Stroke, 2007, 2, 276-278.	5.9	7
254	Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients. Neurologia I Neurochirurgia Polska, 2007, 41, 1-12.	1.2	34
255	Thrombolysis for Stroke in Poland: First 2 Years of Experience. International Journal of Stroke, 2006, 1, 111-112.	5.9	4
256	Gender Differences in Neurological Disease: Role of Estrogens and Cytokines. Endocrine, 2006, 29, 243-256.	2.2	98
257	High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. Journal of Neuroimmunology, 2006, 176, 134-140.	2.3	17
258	p.H1069Q mutation inATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Movement Disorders, 2006, 21, 245-248.	3.9	68
259	Ibuprofen and the mouse model of Parkinson's disease. Annals of Neurology, 2006, 59, 988-989.	5.3	14
260	Acute Ischemic Stroke Care and Outcome in Centers Participating in the Polish National Stroke Prevention and Treatment Registry. Stroke, 2006, 37, 1837-1843.	2.0	29
261	Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clinical Genetics, 2005, 68, 524-532.	2.0	124
262	Wilsonâ€™s diseaseâ€”cause of mortality in 164 patients during 1992â€“2003 observation period. Journal of Neurology, 2005, 252, 698-703.	3.6	89
263	APOE Genotype and Serum Cholesterol in Predicting Risk for Early Death from Ischemic Stroke in Men and Women. Cerebrovascular Diseases, 2005, 20, 291-298.	1.7	12
264	Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases. Current Pharmaceutical Design, 2005, 11, 1017-1030.	1.9	112
265	Influence of Gender on Baseline Features and Clinical Outcomes among 17,370 Patients with Confirmed Ischaemic Stroke in the International Stroke Trial. Neuroepidemiology, 2005, 24, 123-128.	2.3	251
266	Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinsonâ€™s disease. Neuroscience, 2005, 131, 247-254.	2.3	15
267	Underfunding of Stroke Research. Stroke, 2004, 35, 2368-2371.	2.0	40
268	Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Research, 2004, 1019, 144-151.	2.2	41
269	Agreement between the clinical Oxfordshire Community Stroke Project classification and CT findings in Poland. European Journal of Neurology, 2004, 11, 91-96.	3.3	21
270	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 2004, 4, 1307-1318.	3.8	106

#	Article	IF	Citations
271	Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-?-1a treatment in multiple sclerosis patients. Journal of Neurology, 2003, 250, 1229-1236.	3.6	14
272	The Polish Experience in Early Stroke Care. Cerebrovascular Diseases, 2003, 15, 14-15.	1.7	10
273	Self-Rated Emotional Functioning of Patients With Neurological or Asymptomatic Form of Wilsonâ€™s Disease. Clinical Neuropsychologist, 2003, 17, 367-373.	2.3	19
274	Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiologiae Experimentalis, 2003, 63, 117-26.	0.7	33
275	Advanced atherosclerosis of the aortic arch is uncommon in ischemic stroke: An autopsy study. Neurological Research, 2002, 24, 491-494.	1.3	15
276	High early case fatality after ischaemic stroke in Poland: Exploration of possible explanations in the International Stroke Trial. Journal of the Neurological Sciences, 2002, 202, 53-57.	0.6	15
277	Leukoaraiosis and stroke outcome. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 336-340.	1.6	21
278	Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. Movement Disorders, 2002, 17, 1077-1083.	3.9	83
279	Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Medical Science Monitor, 2002, 8, RA165-77.	1.1	69
280	Three novel mutations (P760L, L1305P, Q1351Stop) causing Wilson disease. Human Mutation, 2001, 17, 156-156.	2.5	5
281	Elevated Levels of Anti-Heat Shock Protein Antibodies in Patients with Cerebral Ischemia. Cerebrovascular Diseases, 2001, 12, 235-239.	1.7	46
282	Heart disease contributes to high stroke mortality in Poland. Journal of Stroke and Cerebrovascular Diseases, 2000, 9, 76-78.	1.6	2
283	Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis. European Journal of Neurology, 1999, 6, 347-352.	3.3	14
284	The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse. Experimental Neurology, 1999, 156, 50-61.	4.1	338
285	Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurological Research, 1999, 21, 653-657.	1.3	40
286	Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology, 1998, 39, 167-180.	2.0	261
287	Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. Neurological Research, 1997, 19, 377-379.	1.3	11
288	Interpretation of IST and CAST stroke trials. Lancet, The, 1997, 350, 441-442.	13.7	2

#	Article	IF	Citations
289	Microglial Reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Induced Parkinson's Disease Mice Model. Experimental Neurology, 1996, 5, 137-143.	1.7	245
290	Pargyline pretreatment prevents immunological changes induced by MPTP in mice. Immunopharmacology, 1996, 35, 149-154.	2.0	8
291	Effects of long-term treatment in Wilson's disease withd-penicillamine and zinc sulphate. Journal of Neurology, 1996, 243, 269-273.	3.6	172
292	Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor-? by HLA-DR2+ T cells. Annals of Neurology, 1995, 38, 723-730.	5.3	81
293	Factors predicting 30-day mortality in the Warsaw stroke registry. Journal of Stroke and Cerebrovascular Diseases, 1995, 5, 72-77.	1.6	6
294	Analysis of 30-day stroke mortality in a community-based registry in Warsaw, Poland. Journal of Stroke and Cerebrovascular Diseases, 1994, 4, 63-67.	1.6	8
295	Silent cerebrovascular lesions in patients with first-ever stroke. Journal of Stroke and Cerebrovascular Diseases, 1994, 4, 71-74.	1.6	3
296	Immunological changes in the MPTP-induced Parkinson's disease mouse model. Journal of Neuroimmunology, 1993, 42, 33-37.	2.3	29
297	A Double-Blind Controlled Trial of Naloxone in Early Treatment of Acute Ischemic Stroke. Cerebrovascular Diseases, 1992, 2, 40-43.	1.7	5
298	Microglia and microglia-derived brain macrophages in culture: generation from axotomized rat facial nuclei, identification and characterization in vitro. Brain Research, 1989, 492, 1-14.	2.2	97
299	Effect of Naloxone on Acute Stroke. Pharmacopsychiatry, 1988, 21, 98-100.	3.3	15
300	Reduced binding of3H-spiroperidol to lymphocyte in Wilson's disease. Acta Neurologica Scandinavica, 1984, 69, 298-301.	2.1	10
301	Subacute sclerosing panencephalitis: influence of the clinical course and treatment with isoprinosine on non-specific cell-mediated and humoral immunity. Acta Neurologica Scandinavica, 1983, 67, 275-284.	2.1	7
302	Sensitization of cerebrospinal fluid and peripheral blood lymphocytes to myelin basic protein in multiple sclerosis. Acta Neurologica Scandinavica, 1982, 66, 121-129.	2.1	12
303	Differences between lymphocyte subsets of the cerebrospinal fluid in subacute sclerosing panencephalitis and acute aseptic meningitis. Journal of Neuroimmunology, 1981, 1, 173-181.	2.3	6
304	Induction of fiber outgrowth in PC12 pheochromocytoma cells by a neuronotrophic factor occurring in human tumors. Acta Neuropathologica, 1981, 53, 221-225.	7.7	4
305	Late Onset of Wilson's Disease. Archives of Neurology, 1981, 38, 729.	4.5	30
306	Lymphocyte subpopulations in the cerebrospinal fluid and peripheral blood in multiple sclerosis. Acta Neurologica Scandinavica, 1980, 62, 55-62.	2.1	10

#	Article	IF	Citations
307	Immunological observations on patients with acute cerebral vascular disease. Journal of the Neurological Sciences, 1979, 43, 455-464.	0.6	74
308	The influence of prolonged treatment with D-penicillamine on the immune response in Wilson's disease. European Journal of Clinical Pharmacology, 1977, 12, 265-271.	1.9	12
309	IMMUNOLOGY OF LESCH-NYHAN SYNDROME. Lancet, The, 1976, 307, 863.	13.7	2
310	Immunological observations on patients with Wilson's disease. Journal of the Neurological Sciences, 1976, 29, 411-421.	0.6	18
311	PENICILLAMINE IN MULTIPLE SCLEROSIS. Acta Neurologica Scandinavica, 1976, 54, 281-286.	2.1	3
312	A study of haemolysis in Wilson's disease. Journal of the Neurological Sciences, 1972, 16, 303-314.	0.6	14